ArticleJournal of cachexia, sarcopenia and muscle2024
An Artificial Intelligence Approach for Test-Free Identification of Sarcopenia.
Article in Journal of cachexia, sarcopenia and muscle, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Association between muscle-specific strength and disability in instrumental activities of daily living in patients with chronic kidney disease.International urology and nephrology · 2026Article
- Leveraging interpretable machine learning to identify sarcopenia in middle-aged and older adults with intrinsic capacity decline: an analysis of CHARLS data under AWGS 2025.BMC medical informatics and decision making · 2026Article
- Radiomics-Based Machine Learning for Sarcopenia Detection in Abdominal and Low-Dose CT.Diagnostics (Basel, Switzerland) · 2026Article
- Transformer-based multimodal model for estimation of appendicular lean mass using incomplete chest radiographs and electronic health record.Journal of translational medicine · 2026Article
- Operationalizing the Global Leadership Initiative in Sarcopenia: Muscle-Specific Strength, Optimal Criteria and Clinical Relevance.Journal of cachexia, sarcopenia and muscle · 2026Observational
- Clinical utility of the AITIS model for test-free identification of sarcopenia in patients with stage IV-V non-dialysis-dependent chronic kidney disease.Frontiers in nutrition · 2026Article
- Objective Measures of Physical Functioning, Disabilities in Daily Life and Trends During Ageing: A Repeated Cross-Sectional Study.Journal of cachexia, sarcopenia and muscle · 2025Article
- Towards Sensor-Based Mobility Assessment for Older Adults: A Multimodal Framework Integrating PoseNet Gait Dynamics and InBody Composition.Sensors (Basel, Switzerland) · 2025Article
- Development and Validation of Quantile Regression Forests for Prediction of Reference Quantiles in Handgrip and Chair-Stand Test.Journal of cachexia, sarcopenia and muscle · 2025Article
- Intelligent predictive risk assessment and management of sarcopenia in chronic disease patients using machine learning and a web-based tool.European journal of medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundThe diagnosis of sarcopenia relies extensively on human and equipment resources and requires individuals to personally visit medical institutions. The objective of this study was to develop a test-free, self-assessable approach to identify sarcopenia by utilizing artificial intelligence techniques and representative real-world data.
methodsThis multicentre study enrolled 11 661 middle-aged and older adults from a national survey initialized in 2011. Follow-up data from the baseline cohort collected in 2013 (n = 9403) and 2015 (n = 10 356) were used for validation. Sarcopenia was retrospectively diagnosed using the Asian Working Group for Sarcopenia 2019 framework. Baseline age, sex, height, weight and 20 functional capacity (FC)-related binary indices (activities of daily living = 6, instrumental activities of daily living = 5 and other FC indices = 9) were considered as predictors. Multiple machine learning (ML) models were trained and cross-validated using 70% of the baseline data to predict sarcopenia. The remaining 30% of the baseline data, along with two follow-up datasets (n = 9403 and n = 10 356, respectively), were used to assess model performance.
resultsThe study included 5634 men and 6027 women (median age = 57.0 years). Sarcopenia was identified in 1288 (11.0%) individuals. Among the 20 FC indices, the running/jogging 1 km item showed the highest predictive value for sarcopenia (AUC [95%CI] = 0.633 [0.620-0.647]). From the various ML models assessed, a 24-variable gradient boosting classifier (GBC) model was selected. This GBC model demonstrated favourable performance in predicting sarcopenia in the holdout data (AUC [95%CI] = 0.831 [0.808-0.853], accuracy = 0.889, recall = 0.441, precision = 0.475, F1 score = 0.458, Kappa = 0.396 and Matthews correlation coefficient = 0.396). Further model validation on the temporal scale using two longitudinal datasets also demonstrated good performance (AUC [95%CI]: 0.833 [0.818-0.848] and 0.852 [0.840-0.865], respectively). The model's built-in feature importance ranking and the SHapley Additive exPlanations method revealed that lifting 5 kg and running/jogging 1 km were relatively important variables among the 20 FC items contributing to the model's predictive capacity, respectively. The calibration curve of the model indicated good agreement between predictions and actual observations (Hosmer and Lemeshow p = 0.501, 0.451 and 0.374 for the three test sets, respectively), and decision curve analysis supported its clinical usefulness. The model was implemented as an online web application and exported as a deployable binary file, allowing for flexible, individualized risk assessment.
conclusionsWe developed an artificial intelligence model that can assist in the identification of sarcopenia, particularly in settings lacking the necessary resources for a comprehensive diagnosis. These findings offer potential for improving decision-making and facilitating the development of novel management strategies of sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.